Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Treatment options for CLL patients with poor prognostic markers

Othman Al-Sawaf • 11 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Antibodies
CLL14 CLL17

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses treatment options for chronic lymphocytic leukemia (CLL) patients with poor prognostic markers such as TP53 aberration and unmutated IgHV status. Dr Al-Sawaf highlights both fixed duration approaches and continuous treatment as options for these patients, and the need for head-to-head comparison trials to better understand which option to choose. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Othman Al-Sawaf

1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023
1:43
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals